Form 4: Apimeds Pharmaceuticals Director Acquires Stock Options
SEC Form 4 Filing
Carol A. O'Donnell, a director of Apimeds Pharmaceuticals US, Inc., acquired stock options exercisable for 5,780 shares of common stock.
Summary
- On May 16, 2025, Carol A. O'Donnell, a director of Apimeds Pharmaceuticals US, Inc., acquired stock options to purchase 5,780 shares of the company's common stock at an exercise price of $1.73 per share.
- The options vest fully on May 16, 2026, and expire on May 16, 2035.
- Following the transaction, O'Donnell directly owns options for 5,780 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of transaction: Director acquired stock options. |
| 05/16/2026 | Date the options vest in full and become exercisable. |
| 05/16/2035 | Expiration date of the stock options. |
| 05/20/2025 | Date of Form 4 filing. |
Keywords
stock options, Form 4, director, Apimeds Pharmaceuticals, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.